Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 17, Issue 2, 2017, Pages 223-234

  Gegia, Medea ^a   Winters, Nicholas ^b   Benedetti, Andrea ^b   van Soolingen, Dick ^c   Menzies, Dick ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b MCGILL UNIVERSITY   (Canada)

^c Mycobacterial Reference Lab   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; COHORT ANALYSIS; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; HUMAN; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; CANADA; RECURRENT DISEASE; RETREATMENT; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; CANADA; HUMANS; ISONIAZID; RECURRENCE; RETREATMENT; RIFAMPIN; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

EID: 85006835850     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30407-8     Document Type: Article

References (71)

1. 1 Jenkins, HE, Zignol, M, Cohen, T, Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994–2009. PLoS One, 6, 2014, e22927.
2. 2 WHO. Global tuberculosis control: WHO report 2014, 2015, World Health Organization, Geneva.
3. 3 Wright, A, Zignol, M, Van Deun, A, et al. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373 (2009), 1861–1873.
4. 4 WHO. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update, 2011, World Health Organization, Geneva.
5. 5 American Thoracic Society Infectious Diseases Society of America, Centres for Disease Control. Treatment of tuberculosis. Am J Respir Crit Care Med 167 (2003), 603–662.
6. 6 Menzies, D, Benedetti, A, Paydar, A, et al. Standardized treatment of active tuberculosis in patients with previous preatment and/or with mono-resistance to Isoniazid: a systematic review and meta-analysis. PLoS Med, 6, 2009, e1000150.
7. 7 Tuberculosis Research Centre, Indian Council of Medical Research. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Int J Tuber Lung Dis 1 (1997), 509–517.
8. 8 Hamza, TH, Houwelingen, HC, Stijnen, T, The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 61 (2008), 41–51.
9. 9 Higgins, JP, Thompson, SG, Quantifying heterogeneity in meta-analysis. Stat Med 21 (2002), 1539–1558.
10. 10 Glasziou, PP, Sanders, SL, Investigating causes of heterogeneity in systematic reviews. Stat Med 21 (2002), 1503–1511.
11. 11 Thompson, SG, Sharp, SJ, Explaining heterogeneity in meta-analysis: a comparison of methods. Statist Med 18 (1999), 2693–2708.
12. 12 Poppe de Figeuiredo, F, Alves Brito, A, Laborne Valle, JH, Martins Tavares, P, Linhares Trannin, P, Short duration chemotherapy of pulmonary tuberculosis: a pilot trial. Bull Int Union Tuberc, 49, 1974, 382.
13. 13 Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council. A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong. Tubercle 55 (1974), 1–27.
14. 14 Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months. Am Rev Respir Dis 116 (1977), 807–820.
15. 15 Zierski, M, Bek, E, Bergson, H, Kucharska, A, Szelagowicz, B, Retreatment of chronic pulmonary tuberculosis with regimens including high and low doses of rifampicin in the intermittent phase recent and late results—a controlled comparison study. Bull Int Union Tuberc 51 (1976), 121–126.
16. 16 Third East African/British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report. Am Rev Respir Dis 118 (1978), 39–48.
17. 17 East African/British Medical Research Council. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Lancet 312 (1978), 334–338.
18. 18 Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report. Am Rev Respir Dis 118 (1978), 219–228.
19. 19 Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 119 (1979), 579–585.
20. 20 Tripathy, SP, Madras study of short-course chemotherapy in pulmonary tuberculosis. Bull Int Union Tuberc 54 (1979), 28–30.
21. 21 Zierski, M, Bek, E, Long, MW, Snider, DE Jr, Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis 122 (1980), 879–889.
22. 22 Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 317 (1981), 171–174.
23. 23 East African/British Medical Research Council. Controlled clinical trial of 4 short-couse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tuberc 64 (1983), 153–166.
24. 24 Algerian Working Group/British Medical Research Council. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Am Rev Respir Dis 129 (1984), 921–928.
25. 25 Mazouni, L, Tazir, M, Boulahbal, F, Chaulet, P, Enquête contrôlée comparant trois règimes de chiniothérapie quotidienne de six mois dans la tuberculose pulmonaire, en pratique de routine à Alger. Rev Mal Resp 2 (1985), 209–214.
26. 26 Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 132 (1985), 374–378.
27. 27 Aziz, A, Ishaq, M, Jaffer, NA, Akhwand, R, Bhatti, AH, Clinical trial of two short-course (6-month) regimens and a standard regimen (12-month) chemotherapy in retreatment of pulmonary tuberculosis in Pakistan. Am Rev Resp Dis 134 (1986), 1056–1061.
28. 28 Tanzania/British Medical Research Council. Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 131 (1985), 727–731.
29. 29 Tuberculosis Research Centre Madras. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Am Rev Respir Dis 134 (1986), 27–33.
30. 30 Babu, SO, Aluoch, JA, Githui, WA, et al. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. Tubercle 69 (1988), 5–14.
31. 31 Hong, YP, Kim, SC, Chang, SC, Kim, SJ, Jin, BW, Park, CD, Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions. Tubercle 69 (1988), 241–253.
32. 32 Castelo, A, Jardim, JR, Goihman, S, et al. Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. Lancet 334 (1989), 1173–1176.
33. 33 Hong Kong Chest Service/Tuberculosis Research Centre Madras/British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Am Rev Respir Dis 139 (1989), 871–876.
34. 34 Kenyan/Zambian/British Medical Research Council Collaborative Study. Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 140 (1989), 990–995.
35. 35 Agounitestane, D, Chiheb, M, Khaled, S, Khaled, NA, Boulahbal, F, Chaulet, P, Essai thérapeutique d'une combinaison de trois médicaments essentiels dans la chimiothérapie courte de la tuberculose. Rev Mal Resp 7 (1990), 209–213.
36. 36 Algerian Working Group/British Medical Research Council Cooperative Study. Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Tubercle 72 (1991), 88–100.
37. 37 Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Am Rev Respir Dis 143 (1991), 700–706.
38. 38 Hong Kong Chest Service/Tuberculosis Research Centre/Madras/British Medical Research Council. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 143 (1991), 262–267.
39. 39 Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 143 (1991), 707–712.
40. 40 Chaulet, P, Boulahbal, F, Essai clinique d'une combinaison en proportions fixes de trois medicaments dans le traitement de la tuberculose. Tuberc Lung Dis 76 (1995), 407–412.
41. 41 Tanzania British Medical Research Council Collaborative Investigation. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. S Afr Med J 86 (1996), 960–965.
42. 42 Santha, T, Rehman, F, Mitchison, DA, et al. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis—a unique approach. Trop Med Int Health 9 (2004), 551–558.
43. 43 Swaminathan, S, Narendran, G, Venkatesan, P, et al. Efficacy of a 6-month versus 9-month intermittent tretment regimen in HIV-infected patients with tuberculosis. Am J Respir Crit Care Med 181 (2010), 743–751.
44. 44 Gyselen, A, Verbist, L, Cosemans, J, Lacquet, LM, Vandenbergh, E, Rifampin and ethambutol in the retreatment of advanced pulmonary tuberculosis. Am Rev Resp Dis, 98, 1968, 933.
45. 45 Mital, OP, Narang, RK, Sachan, AS, Rifampicin-ethambutol in retreatment of pulmonary tuberculosis. Indian J Chest Dis Allied Sci 18 (1976), 141–145.
46. 46 Davies, GR, Connolly, C, Sturm, AW, McAdam, K, Wilkinson, D, Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa. AIDS 13 (1999), 811–817.
47. 47 Espinal, MA, Kim, SJ, Suarez, PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis—treatment outcomes in 6 countries. JAMA 283 (2000), 2537–2545.
48. 48 Nolan, CM, Goldberg, SV, Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Int J Tuber Lung Dis 6 (2002), 952–958.
49. 49 Seung, KJ, Gelmanova, IE, Peremitin, GG, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 39 (2004), 1321–1328.
50. 50 Yoshiyama, T, Yanai, H, Rhiengtong, D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 8 (2004), 31–38.
51. 51 Thomas, A, Gopi, PG, Santha, T, et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis 9 (2005), 556–561.
52. 52 Cox, H, Kebede, Y, Allamuratova, S, et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med, 3, 2006, e384.
53. 53 Tuberculosis Research Centre, Indian Council of Medical Research. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis. Indian J Tuberc 54 (2007), 84–90.
54. 54 Kim, YH, Suh, GY, Chung, MP, et al. Treatment of isoniazid-resistant pulmonary tuberculosis. BMC Infect Dis, 8, 2008, 6.
55. 55 Temple, B, Ayakaka, I, Ogwang, S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala. Clin Infect Dis 47 (2008), 1126–1134.
56. 56 Tabarsi, P, Baghaei, P, Hemmati, P, et al. Comparison of the effectiveness of 2 treatment regimens in patients with isoniazid-resistant tuberculosis. Eastern Med Health J 15 (2009), 1346–1350.
57. 57 Bonnet, M, Yesilkaya, H, Jarosz, T, et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drugs resistance amplification and re-infection. PloS One, 6, 2011, e23081.
58. 58 Yoshiyama, T, Shrestha, B, Maharjan, B, Risk of relapse and failure after retreatment with the category II regimen in Nepal. Int J Tuber Lung Dis 14 (2010), 1418–1423.
59. 59 Gegia, M, Cohen, T, Kalandadze, I, Vashakidze, I, Furin, J, Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007–2009. Int J Tuber Lung Dis 16 (2012), 812–816.
60. 60 Deepa, D, Achanta, S, Jaju, J, et al. The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh India. PLoS One, 8, 2013, e76189.
61. 61 Huyen, MN, Cobelens, FG, Buu, TN, et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother 57 (2013), 3620–3627.
62. 62 Reves, R, Heilig, CM, Tapy, JM, et al. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. Int J Tuber Lung Dis 18 (2014), 571–580.
63. 63 Espinal, MA, Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int J Tuberc Lung Dis 7 (2003), 607–608.
64. 64 Rusen, ID, Tuberculosis retreatment: a topic whose time has come. Int J Tuberc Lung Dis, 13, 2009, 1192.
65. 65 Jasmer, RM, Daley, CL, Rifampin and pyrazinamide for treatment of latent tuberculosis infection. Am J Respir Crit Care Med 167 (2003), 809–812.
66. 66 Gao, XF, Wang, L, Liu, GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 10 (2006), 1080–1090.
67. 67 Center for Disease Control. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. Morb Mortal Wkly Rep 50 (2001), 289–291.
68. 68 Burman, W, Goldberg, S, Johnson, JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Resp Crit Care Med, 174, 2006, 331.
69. 69 Dorman, SE, Johnson, JL, Goldberg, S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180 (2009), 273–280.
70. 70 Jawahar, MS, Banurekha, VV, Paramasivan, CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One, 8, 2013, e67030.
71. 71 Gillespie, SH, Crook, AM, McHugh, TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Eng J Med 371 (2014), 1577–1587.